Identifying SARS-CoV-2 Plasma Donors: An Alternative Assay
Identifying suitable COVID-19 convalescent plasma donors using a different approach
Olivia Gaskill | | Quick Read
Convalescent plasma therapy is under consideration for the treatment of COVID-19 patients, but finding suitable donors by measuring SARS-CoV-2 virus-neutralizing (VN) antibodies in the blood presents a challenge. The technique is complicated, labor-intensive, and restricted to biosafety level 3 laboratories. Researchers at the University of Texas at Austin and Houston Methodist recognized the need for a different approach and used accessible, easy-to-use ELISA to measure the relationship between anti-spike ectodomain (ECD), anti-receptor binding domain (RBD) IgG titers, and SARS-CoV-2 VN titers (1).
Testing 2,814 plasma samples from asymptomatic adults, they found a strong positive correlation between anti-RBD and anti-ECD IgG titers and VN antibody levels at or above the FDA-recommended levels recommended for COVID-19 convalescent plasma. As viable alternatives to VN titers, these assays could enable more widespread identification of suitable convalescent plasma donors.
Subscribe to The Pathologist Newsletters
- E Salazar et al., J Clin Invest, [ePub ahead of print] (2020). PMID: 32910806.